GET DAILY SIGNALSSerina Therapeutics (SER) Q3 2026 Results: Narrower Loss Than Expected
Key Takeaways
- Serina Therapeutics posted a net loss attributable to common stockholders of $7.9 million, or $(0.31) per basic and diluted share, for the third quarter of 2026.
- The per-share loss of $(0.31) was narrower than the consensus estimate of about $(0.34), driven by a higher share count following recent financings.
- Total revenues were $125,000 in contract revenues, compared with no revenue in the same quarter a year earlier.
- Research and development (R&D) expenses rose to $4.6 million as the company advanced its lead program, SER-252, in a Phase 1b study for Parkinson's disease.
- Cash and cash equivalents totaled $19.4 million as of September 30, 2026, supporting ongoing clinical development.
Earnings Context and Clinical Focus
Serina Therapeutics is a clinical-stage biotechnology company whose stock trades on the NYSE American. The company is advancing SER-252 (POZ-apomorphine), an investigational therapy designed to deliver continuous dopaminergic stimulation (CDS) for people with Parkinson's disease who experience motor complications. For a pre-revenue biotech, the quarterly earnings release matters less for top-line sales and more for the signals it provides about clinical progress, spending discipline, and cash runway. Investors read these reports closely to gauge whether the lead program remains on track and whether the company has enough capital to reach its next key milestones. The third-quarter update therefore offers an important checkpoint on both execution and financial health. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
For the three months ended September 30, 2026, Serina Therapeutics reported total revenues of $125,000, all from contract revenues, versus no revenue in the prior-year period. Operating expenses rose to $8.0 million from $6.4 million a year earlier, reflecting heavier investment in the SER-252 clinical program. Research and development expenses increased to $4.6 million from $3.6 million, while general and administrative expenses climbed to $3.3 million from $2.7 million.
The net loss attributable to common stockholders was $7.9 million, or $(0.31) per basic and diluted share, compared with a net loss of $4.7 million, or $(0.45) per share, in the same quarter of 2025. Although the dollar-amount loss widened year over year, the per-share figure came in narrower than the roughly $(0.34) analysts had anticipated, largely because of a higher share count following recent equity financings. Cash and cash equivalents stood at $19.4 million at quarter-end.
Market Reaction and Investor Sentiment
Sentiment around Serina Therapeutics remains closely tied to clinical milestones rather than quarterly financials. Heading into the report, the key question was whether the company had maintained sufficient momentum in its SER-252 Phase 1b study while keeping a manageable burn rate. The narrower-than-expected per-share loss, combined with confirmation that the program continues to advance, was a generally supportive signal. At the same time, the widening dollar-amount loss and rising R&D spend underscore that the company remains in a capital-intensive stage, which can keep volatility elevated in the shares as investors weigh progress against future financing needs.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will focus primarily on the SER-252 clinical program. The Phase 1b study is a randomized, double-blind, placebo-controlled trial evaluating single-ascending and multiple-ascending doses of subcutaneous SER-252 in adults with Parkinson's disease and motor fluctuations. Top-line data from the single-ascending-dose arm are targeted for the first half of 2027, making that a key upcoming catalyst.
Beyond the data readout, several factors deserve attention. First, spending discipline will matter: research and development costs are rising as the trial scales, and investors will want to see that the company can fund its pipeline without excessive dilution. The $19.4 million cash position provides a cushion, but the timing and terms of any future capital raise will be closely watched. Finally, the company's broader partnership strategy may influence the outlook. In mid-2026, Serina entered a development partnership with Gannet BioChem to support process development, scale-up, and manufacturing for SER-252, a step aimed at strengthening technical capabilities ahead of later-stage work. Continued progress on clinical execution, cash management, and potential collaborations will shape how investors view the company in the quarters ahead. From what I see, this remains an important area to watch closely.
Using AI Tools in My Research Process
I’ve found Tickeron’s AI Screener helpful for quickly filtering biotech names by technical patterns, fundamentals, and volatility. It lets me scan for comparable companies and spot potential ideas without spending hours on manual checks, which fits well when reviewing clinical-stage stories like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SER's RSI Indicator recovers from oversold territory
The RSI Oscillator for SER moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 27 similar instances when the indicator left oversold territory. In 26 of the 27 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +18.29% 3-day Advance, the price is estimated to grow further. Considering data from situations where SER advanced for three days, in 171 of 205 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
SER may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 04, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SER as a result. In 113 of 122 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for SER turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 55 similar instances when the indicator turned negative. In 49 of the 55 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
The 50-day moving average for SER moved below the 200-day moving average on November 06, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SER declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for SER entered a downward trend on October 29, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.871) is normal, around the industry mean (3.498). P/E Ratio (-0.738) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (204.082) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. SER’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SER’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement